Ovulation

What it is

Ovulation is the release of a mature egg from an ovarian follicle, an event that creates the fertile window — the roughly 6-day span each cycle during which conception is biologically possible. It is the central hormonal event of the menstrual cycle, and research published in Human Reproduction found that on every day between cycle days 6 and 21, at least 10% of women with regular cycles were already within their fertile window — meaning the textbook "day 14" rule misrepresents most people's biology. In Canada, ovulatory dysfunction is among the leading causes of infertility assessed through provincial fertility programs and is a core diagnostic target in SOGC clinical practice guidelines on anovulation and polycystic ovary syndrome (PCOS).

Ovulation, also called the fertile window when used in the context of conception timing, marks the transition between the follicular phase and the luteal phase of the menstrual cycle.

Causes and mechanism

The menstrual cycle is governed by a hormonal cascade originating in the hypothalamus and pituitary gland:

1. Follicular phase (days 1–~14 in a 28-day cycle): Follicle-stimulating hormone (FSH) recruits a cohort of ovarian follicles beginning around day 1–4. One dominant follicle emerges and produces rising estradiol levels over roughly 10–16 days.
2. LH surge: Estradiol rising above ~200 pg/mL for at least 48 hours triggers a sharp luteinizing hormone (LH) surge from the pituitary. Ovulation follows approximately 36–40 hours after the surge begins.
3. Ovulation: The dominant follicle ruptures and releases the egg into the fallopian tube, where it remains viable for 12–24 hours.
4. Luteal phase (days ~15–28): The ruptured follicle becomes the corpus luteum and secretes progesterone for approximately 14 days — the most consistent phase-length across all cycle lengths. If fertilization does not occur, progesterone falls, the uterine lining sheds, and a new cycle begins.

Sperm can survive in the female reproductive tract for up to 5–7 days, which is why the fertile window extends several days before ovulation, not just on the day itself.

Phase	Approximate days (28-day cycle)	Key hormone
Menstruation	1–5	Estrogen and progesterone low
Follicular / proliferative	1–13	FSH → rising estradiol
Ovulation	~14 (range: day 6–21+)	LH surge
Luteal / secretory	15–28	Progesterone (constant ~14 days)

Cycle length variability comes almost entirely from the follicular phase (10–16 days), not the luteal phase.

Symptoms and diagnosis

Many people notice physical signs around ovulation, though none is reliable enough to confirm the event on its own:

• Mittelschmerz: Unilateral pelvic pain or cramping lasting minutes to hours, occurring in roughly 20% of people
• Cervical mucus changes: Discharge becomes clear, slippery, and stretchy ("egg-white" consistency) in the days before ovulation
• Basal body temperature (BBT) rise: A sustained increase of 0.2–0.5 °C signals that ovulation has already occurred; BBT charting confirms past ovulation but cannot predict it in real time
• LH urine testing: Over-the-counter LH surge test strips (available at any Canadian pharmacy, including Shoppers Drug Mart and Pharmaprix) detect the LH surge 24–36 hours before egg release and are the most practical home predictor
• Transvaginal ultrasound: The clinical gold standard for confirming follicle development and rupture; ordered through a physician referral and available at LifeLabs or Dynacare-affiliated clinics in most provinces
• Serum progesterone (day 21): A mid-luteal progesterone level above 16–30 nmol/L (Canadian lab reference ranges vary slightly) confirms that ovulation occurred in that cycle

Absent or irregular ovulation — anovulation — is diagnosed when cycles are consistently shorter than 21 days or longer than 35 days, or when mid-luteal progesterone is low.

Treatment options

Treatment depends entirely on whether the goal is to achieve or to avoid pregnancy, and on the underlying cause of any ovulatory dysfunction.

For anovulation / infertility:

• Letrozole (an aromatase inhibitor) is now the first-line ovulation induction agent recommended by the SOGC for people with PCOS-related anovulation, with live-birth rates of approximately 27% per cycle in clinical trials
• Clomiphene citrate remains widely used and is covered under some provincial drug benefit plans (coverage varies by province; Ontario's OHIP+ does not include it, but some private plans do)
• Gonadotropin injections (FSH/LH) are used in specialist fertility clinics when oral agents fail
• Metformin may restore ovulation in insulin-resistant PCOS, though evidence for it as a standalone ovulation induction agent is weaker than for letrozole

For fertility awareness / contraception:

• Fertility awareness-based methods (FABMs) use BBT, cervical mucus, and/or LH testing to identify the fertile window. With perfect use, failure rates are reported at 1–5% per year, but typical-use failure rates are considerably higher (up to 24% for some methods)
• Hormonal contraceptives (combined oral contraceptive pill, patch, hormonal IUD, injectable) suppress ovulation as their primary or secondary mechanism

When to see a clinician in Canada

See a family physician or OB-GYN if:

• Cycles are consistently outside the 21–35 day range
• You have been trying to conceive for 12 months without success (or 6 months if you are over 35)
• Mid-luteal progesterone testing suggests anovulation
• You experience severe mid-cycle pain (Mittelschmerz that is debilitating warrants investigation for endometriosis or ovarian cysts)

Canadian patients can access initial ovulatory workup through a family physician; referral to a reproductive endocrinologist is typically required for gonadotropin therapy or IVF. Telehealth platforms operating in Canada — including Maple, Felix, and Cleo — can facilitate initial hormone testing orders and referrals in most provinces, though complex fertility treatment requires in-person specialist care.

Limitations and open questions

Research is still emerging on several aspects of ovulation biology relevant to clinical practice. The accuracy of consumer wearable devices (temperature sensors, heart-rate variability trackers) for predicting ovulation has not been validated in large prospective trials, and Health Canada has not yet issued specific guidance on their use for fertility or contraception purposes. The fertile window boundaries used in most clinical guidelines are derived from studies of predominantly white, regularly cycling participants; how well these ranges generalize across diverse cycle lengths, ages, and ethnicities is not fully established. The optimal mid-luteal progesterone threshold for confirming ovulation also varies across Canadian laboratory reference ranges, and no national standardization exists. Finally, the long-term hormonal consequences of repeated ovulation suppression (e.g., decades of combined oral contraceptive use) on subsequent fertility remain an area of active investigation, with current evidence generally reassuring but not definitive.